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OBJECTIVES: The objective of this study is to examine the relationship between 
pre-existing Type 2 Diabetes Mellitus (T2DM) and all-cause mortality among elderly 
Medicare beneficiaries with Colorectal Cancer (CRC), after controlling for other risk 
factors (sex, age, race, co-occurring chronic conditions and office visits prior to 
cancer diagnosis, cancer stage, site, treatment, region and rurality). METHODS: A 
retrospective cohort design was used. The data were derived from the Surveillance, 
Epidemiology, and End Results (SEER) cancer registries linked with Medicare claims 
files. The final study cohort consisted of elderly Medicare beneficiaries (age > 66 
years) who were diagnosed with incident CRC between 2003 and 2008 and continu-
ously enrolled in fee-for-service Medicare Part A and Part B (N = 42,304). Pre-existing 
T2DM was identified with ICD-9-CM (International Classification of Diseases, 9thre-
vision, clinical modification) codes during the 12 months prior to the diagnosis of 
CRC. Time-to-death was calculated in months. Log-rank tests and Cox proportional 
hazards, non-repeatable events regression model were used to test the unadjusted 
and adjusted associations respectively. RESULTS: In our study cohort 29.8% had 
pre-existing T2DM; 44.2% with T2DM died and 41.6% without T2DM died within 
5-years. Median months to death for those with T2DM was 58 (95%CI = 57.9, 58.8) and 
without T2DM was 59 (95%CI = 58.8, 59.1). After adjusting for other risk factors, CRC 
patients with pre-existing T2DM had moderately higher risk for all-cause mortality 
(HR 1.12, 95% CI 1.08, 1.16). Except for tumor location, rurality, region, and hyperten-
sion all other factors were significantly associated with mortality. CONCLUSIONS: 
Elderly Medicare beneficiaries with incident CRC and pre-existing T2DM had mod-
erately higher risk of all-cause mortality. Future research needs to examine whether 
T2DM management reduces the hazards of all-cause mortality among patients with 
T2DM and incident CRC.
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OBJECTIVES: Previous randomized trials and observational studies have shown 
only comparable survival benefits for colon cancer patients undergoing colectomy 
with laparoscopic versus conventional open surgery. Although laparoscopic surgery 
has become a preferred approach, its survival benefits have not been adequately 
examined in a recent colon cancer cohort. We therefore assessed in a real-world 
Medicare population short- and long-term survival among early-stage colon cancer 
patients treated with laparoscopic-assisted colectomy (LAC) versus open colectomy 
(OC). METHODS: In this retrospective observational cohort study, early-stage colon 
cancer patients aged ≥ 65 years who received colectomy within 6 months of diag-
nosis were selected from the Surveillance Epidemiology and End Results-Medicare 
database (2004-2009). Patients undergoing LAC were propensity matched to those 
receiving OC on demographic and clinical characteristics (stage at diagnosis, tumor 
size, and comorbidities). Short-term (1-year) and long-term (5-year) overall survival 
rates, and survival times were assessed using Kaplan-Meier methods for the overall 
cohort and separately by patients diagnosed with local- versus regional-stage dis-
ease. RESULTS: A total of 10,073 early-stage cancer patients met the study inclusion 
criteria (55% female; median age 77.8 years). Of total, 60.2% were diagnosed with 
local-stage and 39.8% with regional-stage disease at diagnosis. The 1-year survival 
did not differ between LAC and OC groups for the overall cohort and local-stage 
patients, but was significantly higher in the LAC group for regional-stage patients 
(98.4% vs. 97.4%; p< 0.05). The 5-year survival was significantly better in the LAC 
(vs. OC) group for the overall cohort (63.2% vs. 59.8%; p< 0.05) and regional-stage 
patients (54.9% vs. 48.5%; p< 0.01). Regional-stage patients treated with LAC also 
had longer survival time (5.5 vs. 4.7 years; p< 0.01). CONCLUSIONS: Results of this 
study indicate that LAC was associated with greater long-term overall survival rate 
and survival time versus OC among elderly early-stage colon cancer patients, par-
ticularly those with regional-stage disease at diagnosis.
PCN31
overaLL SurvivaL iN PoSt-meNoPauSaL WomeN With hr+/her2- 
metaStatiC breaSt CaNCer treated With 1St-LiNe eNdoCriNe theraPy 
vS. ChemotheraPy
Vekeman F.1, Hao Y.2, Cheng W.Y.3, Fortier J.4, Robitaille M.5, Duh M.S.6
1Groupe d’analyse, Montreal, QC, Canada, 2Novartis Pharmaceuticals Corporation, East Hanover, 
NJ, USA, 3Analysis Group, Boston, MA, USA, 4Groupe d’analyse, Ltée, Montreal, QC, Canada, 
5Groupe d’analyse, ltée, Montreal, QC, Canada, 6Analysis Group, Inc., Boston, MA, USA
OBJECTIVES: As newer treatment options become available to postmenopausal 
women with HR+/HER2- metastatic breast cancer (mBC), understanding the rela-
tive survival benefit of different treatment options and sequencing is of increas-
ing clinical importance. This study compared overall survival (OS) in patients with 
HR+/HER2- mBC whose 1st-line therapy was endocrine therapy (1st-line endo) 
vs. chemotherapy (1st-line chemo) in real-world settings. METHODS: Data were 
extracted from a community oncology electronic medical records database from 
Altos Solutions. Eligible patients were postmenopausal women, with ≥ 1 medical 
record with a BC diagnosis, confirmed HR+/HER2- status, and 1st mBC diagnosis 
(index date) after July 1, 2012. OS between 1st-line endo and 1st-line chemo patients 
was compared using cumulative proportion of deaths and Cox proportional hazard 
regressions controlling for age, race, region, insurance type, comorbidities, disease 
recurrence, and metastatic sites. RESULTS: Among the 1,051 patients meeting the 
eligibility criteria, 676 (64.3%) received 1st-line endo and 375 (35.7%) received 1st-
line chemo. 1st-line endo patients were older (68.1 vs. 64.4 years, p< 0.001) and were 
more often Caucasian (74.1% vs. 65.9%, p= 0.005) compared with 1st-line chemo 
patients. Site of metastases was known in 57.5% of 1st-line endo and 59.2% of 
1st-line chemo patients, with bone being the most common site (48.8% vs. 40.3%, 
p= 0.008). The cumulative proportion of deaths was 5.9% vs. 10.7% (p= 0.005), 10.4% 
vs. 14.7% (p= 0.039), and 12.0% vs. 17.3% (p= 0.016) at 6, 12, and 18 months, respec-
tively. Patients receiving 1st-line endo had better OS at 6 (adjusted hazard ratio [HR]: 
OBJECTIVES: Basal Cell Carcinoma (BCC), a subset of non-melanoma skin cancer 
(NMSC), is the most common cancer in the United States. Previous studies using 
secondary data have been unable to characterize the BCC population, as they were 
completed prior to the release of BCC-specific ICD-9 codes in 2011. The objective 
of this study was to estimate the incidence and prevalence of BCC in a commer-
cially insured US population. METHODS: This was a retrospective study using the 
MarketScan Commercial and Medicare Supplemental Database. Patients included 
were aged ≥ 18 years with ≥ 2 claims for BCC in any position, separated by 60 ≤ 
days ≤ 180 in the identification period 10/1/11 to 9/30/12. Patients were continu-
ously enrolled in medical and pharmacy benefits in the 12 months prior to and 
following the first observed claim (index date). The cohort was further categorized 
as having incident or prevalent BCC, based on the absence or presence of a NMSC 
diagnosis code in the year prior to the index date. Descriptive statistics were per-
formed on baseline demographics and clinical characteristics. RESULTS: A total 
of 19,704 patients with BCC were identified, of whom 12,299 (62.4%) were incident 
and 7,405 (36.6%) were prevalent cases. The majority of patients were male (overall: 
59%, incident: 55%, and; prevalent: 67%, respectively). The mean age (SD) of the BCC 
cohort was 66 (13.8) and patients with incident disease were younger 64 (13.7) than 
patients with prevalent disease 69 (13.5). Mean Charlson Comorbidity Index scores 
were higher in the prevalent cohort (1.5 vs 1.0) and were largely driven by rates of 
malignancy (21.9% vs. 12.6%), diabetes (20.1% vs. 17.7%), and chronic obstructive 
pulmonary disorder (12.8% vs. 10.8%). CONCLUSIONS: In this commercially insured 
population, patients with prevalent BCC are more likely to be male, older, and have 
higher rates of comorbidities than patients with incident disease.
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OBJECTIVES: Explore epidemiology and drug treatment of radioactive iodine-refrac-
tory differentiated thyroid cancer (RR-DTC) in EU5. METHODS: Epidemiology of 
RR-DTC was derived from the Kantar Health (KH) CancerMPact database, sources 
for which include country specific cancer registries, published scientific studies 
and proprietary physician surveys comprising 81 doctors seeing a total of 3,985 
patients per month. Data specific to treatment of RR-DTC was derived from patient 
chart review studies conducted by KH. Age and gender specific incidence rates, 
annual stage specific progression rates and annual stage specific survival rates 
are used to calculate total number of surviving patients at a specific stage up to 
10 years after diagnosis. RESULTS: Incidence of thyroid cancer ranged between 5 
- 20 per 100K population across EU-5 (UK-4.8, Germany-8.4, France-13.4, Italy-20.3, 
Spain-7.2). Among all thyroid patients, % DTC showed less variation: 76% (UK), 83% 
(Germany), 87% Italy, 88% (Spain), 91% (France). Among DTC, % RR was very similar 
(range 26% - 33%). Among RR DTC, 23% received watch and wait, 33% non-systemic 
management and 44% systemic therapy. Among those receiving systemic therapy, 
48% received chemotherapy, 46% received tyrosine kinase inhibitors (TKI) and 6% 
BRAF inhibitors. Among those receiving chemotherapy, 50% received doxorubicin, 
either as monotherapy or part of a multi drug regimen and 20% received cisplatin. 
Among those receiving a TKI, 51% received sorafenib, 28% sunitinib. CONCLUSIONS: 
Among RR DTC patients treated with systemic therapy, chemotherapy and TKIs 
are used most often. The most common chemotherapy is a doxorubicin containing 
regimen and sorafenib is the most common TKI used.
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OBJECTIVES: Prostate cancer (PC) patients with bone metastases experience symp-
toms including debilitating pain that is associated with increased morbidity and 
mortality. Opiates in conjunction with other treatments are recommended for the 
management of severe pain, but real world data on their use in PC are limited. This 
study estimates the prevalence of and predictors for opioid use in PC patients with 
bone metastases. METHODS: Electronic medical records (EMR) from US community 
oncology clinics captured in OncoEMR® database were used to identify PC patients 
with bone metastases. Opioid use was identified from EMR, while evidence of bone 
pain and skeletal-related events (SREs), including pathological fracture, surgery, radio-
therapy to bone and spinal cord compression were extracted from patients’ medical 
charts. Prevalence of opioid use was evaluated. Predictors for opioid vs. non-opioid 
analgesic use for pain were identified using a multivariate logistic model. RESULTS: 
In the study cohort of 1,520 PC patients with bone metastases, the average age was 
73.6 years and mean follow-up from bone metastases was 13.8 months. In the sub-
set with evidence of bone pain (N= 927), 63% were opioid users, of whom 14% were 
chronic users. Multivariate regression analyses revealed that SREs significantly 
increased the opioid use risk by 3.21-fold (95% CI: 2.38-4.32), with the following addi-
tional significant risk factors: Medicare vs. other/no insurance (OR= 1.54, 95% CI: 1.13, 
2.10), chemotherapy (OR= 3.34, 95% CI: 2.17, 5.13), and NSAIDs use (OR= 1.90, 95% CI: 
1.25, 2.88). CONCLUSIONS: SREs are a significant predictor for opioid use. 37% of 
the patients with bone pain had no documented use of opioids. Pain and symptom 
palliation is a significant management issue in PC. It is important to choose appropri-
ate treatments for patients that delay or prevent SREs and effectively control pain.
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in a hypothetical ten-million member health plan over a 3-year horizon. Estimates 
of plan cancer rates and utilization of HEC and MEC therapies were derived from 
epidemiological and market data. Treatment costs were computed using standard 
prescribing dosages, U.S. drug cost listings and simple reimbursement and dis-
pensing assumptions. Uptake of NEPA was calculated at 5% a year for 3 years, and 
competing antiemetic therapies were reduced proportionately based on initial share 
assumptions. RESULTS: A total of 54,000 patients with cancer were identified in the 
model scenario. Of these, 9,882 (18.3%) would receive HEC and 3,949 (7.3%) would 
receive MEC requiring combination therapy, for a total of 13,830 eligible for NEPA. 
Cost of CINV prevention prior to the adoption of NEPA was estimated at $40.96 mil-
lion. Following adoption of NEPA, cumulative costs were reduced by nearly $652K by 
the end of year 3. Calculations using PMPM estimates showed cumulative savings 
of $0.002 in year 1, $0.004 in year 2, and $0.005 in year 3. CONCLUSIONS: Results of 
the model indicate that adoption of NEPA for the prevention of CINV may have a 
relatively neutral impact on a U.S. health plan budget. Additionally, these estimates 
do not include savings from a potential reduction in the overall rate of CINV.
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OBJECTIVES: To evaluate the cost of lung cancer treatment in Brazil from the 
perspective of private hospitals and identify the major cost drivers. METHODS: 
Orizon administrative claims database containing over 18 million lives was used 
to identify patients with lung cancer using the following ICD-10 codes: C34, C34.9, 
C34.0, C34.1, C34.3, C34.8, C34.2 between the period of November 2010 to October 
2013. Only patients receiving traditional chemotherapy for their lung cancer were 
included in the analysis. RESULTS: A total of 11,348 patients were identified with 
lung cancer over the analysis period. The study population was 54% men, 62 years 
old on average, and received treatment for a mean duration of 5,5 months. Of the 
11,348 patients, 3,076 were hospitalized and 8,272 received outpatient care. Forty-
nine percent of those hospitalized also received outpatient care. For patients who 
were hospitalized, each patient had, on average, 4.63 hospitalizations with an aver-
age length of stay of 9.55 days. The average cost per patient hospitalized was BRL 
34,904, with approximately 25.67% of the total hospital cost spent on drugs and the 
remainder spent on fees, supplies, exams and procedures (24.41%, 37.31%, 5.71% 
and 6.89% respectively). For outpatient care, the average cost per patient was BRL 
22,746 with 87.61% of the total outpatient care cost spent on drug expenses and 
the remainder spent on fees, supplies, exams, and procedures (1.73%, 4.02%, 3.76% 
and 2.88% respectively). CONCLUSIONS: The economic burden of lung cancer in 
Brazil could be reduced especially in outpatient care if oral treatments instead of 
infusion-based treatments were used (e.g., avoidance of infusion-related resources 
such as fees, procedures and supplies), which could represent a reduction of 8.63% 
or BRL 1,956 per lung cancer patient.
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OBJECTIVES: Clinical research has demonstrated that laparoscopic liver resec-
tion for hepatocellular carcinoma or secondary colorectal metastases provides 
oncologically equivalent patient outcomes when compared to open liver resection, 
while also providing a statistically significant reduction in postoperative complica-
tions. Approximately 16% of all liver resections in Canada are performed lapras-
copically with a compound annual growth rate of 16%. In the Canadian healthcare 
environment hospitals face constrained budgets and it is critical to demonstrate 
the impact of laparoscopic liver resection to increase procedure volume. This 
study was conducted to determine the budget impact of increasing the propor-
tion of laparoscopic vs. open liver resection in a Canadian hospital. METHODS: 
We examined the budget impact of increasing the percentage of laparoscopic liver 
cases from 16% to 40%, while decreasing the number of open cases proportion-
ately in a hospital that performs 50 resections annually. The model incorporates 
the costs associated with surgery, length of stay (taking into account facility and 
staff costs) and postoperative complications. The cost data used in the model 
was obtained from peer reviewed literature, the Ontario Case Costing Initiative 
and costing data from a large Canadian hospital. Data on patient outcomes was 
obtained from published meta-analyses. A multivariate sensitivity analysis using 
a Monte Carlo simulation was completed to ensure scientific rigour. RESULTS: 
Laparoscopic liver resections are associated with higher device costs, but similar 
overall procedure costs. The additional device cost is offset by a shorter length of 
stay and lower rate of post-operative complications. The model establishes that 
for a Canadian hospital performing 50 liver resections increasing the proportion 
of laparoscopic cases from 16% to 40% allows for a potential cost savings of CAD 
$50,730 annually. CONCLUSIONS: In a Canadian hospital, laparoscopic liver resec-
tion is a more cost-effective procedure for hepatocellular carcinoma or secondary 
colorectal metastases when compared to open resection.
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OBJECTIVES: Estimate the annual economic impact of the introduction of axitinib as 
a therapy for metastatic renal cell carcinoma (mRCC) in the budget of the Ministry 
0.50, p= 0.004), 12 (HR: 0.60, p= 0.009), and 18 (HR: 0.58, p= 0.002) months compared 
to patients receiving 1st-line chemo (patients with known site of metastases: 0.51 
[p= 0.031], 0.61 [p= 0.049], and 0.63 [p= 0.045], respectively) after adjusting for patient 
characteristics. CONCLUSIONS: Compared to chemotherapy, early endocrine ther-
apy may be associated with better survival in postmenopausal women with HR+/
HER2- mBC after adjusting for patient characteristics.
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OBJECTIVES: In oncology trials, it is common practice to offer patients the possibility 
to switch from their randomized treatment to another active treatment upon dis-
ease progression. When patients switch to, and benefit from, active post-progression 
therapies which do not form part of the standard treatment pathway, a standard 
intention-to-treat (ITT) analysis may inaccurately estimate the ‘‘true’’ overall survival 
(OS) benefit associated with the investigational product [Latimer et al, 2014]. Using 
published data from the interim analysis of the PREVAIL study [Beer et al, 2014], 
we estimated the effects of enzalutamide compared to placebo on OS, adjusting for 
the potential confounding effects of switching to antineoplastic therapies that do 
not form part of the standard mCRPC treatment pathway in the UK. METHODS: 
Published treatment switching adjustment methods were applied including the 
Inverse Probability of Censoring Weights (IPCW) and a two-stage accelerated failure 
time model. The suitability of each method was evaluated by examining the study 
characteristics, the treatment switching mechanism, and by assessing the plausi-
bility of the underlying assumptions of the models in the context of the PREVAIL 
study. RESULTS: Overall, 180/845 (21%) patients in the placebo arm and 129/872 (15%) 
patients in the enzalutamide arm of PREVAIL switched to non-standard antineoplastic 
therapies. The unadjusted ITT analysis for OS resulted in a hazard ratio (HR) of 0.706 
(95% CI: 0.595 - 0.837) for enzalutamide compared to placebo, which was reduced 
to 0.662 (95% CI: 0.568 -0.809) using the two-stage method with no recensoring and 
0.625 (95% CI: 0.517 - 0.752) using the IPCW method. CONCLUSIONS: Adjusting for 
non-standard subsequent therapies given in PREVAIL resulted in a larger estimated 
treatment effect on OS associated with enzalutamide. This suggests that receipt of 
non-standard subsequent antineoplastic therapies caused the ITT analysis to under-
estimate the true treatment effect of enzalutamide on OS.
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OBJECTIVES: In the last 3 years, many new advanced melanoma treatments have 
come to market. Ipilimumab was the first compound to demonstrate a statistically 
significant improvement in overall survival in two Phase III RCTs and observational 
studies, with prolonged long-term survival up to 10 years. METHODS: Data from 
the advanced melanoma trials: CA184-024, MDX010-20 and BRIM-3 were used to 
develop an economic model in the UK and to predict the conditional survival of 
patients treated with ipilimumab, dacarbazine and vemurafenib who survived 2 
years. Dabrafenib, pembrolizumab and nivolumab were not valid UK comparators. The 
model uses patient level Kaplan–Meier data for the first 2 years for ipilimumab and 
dacarbazine, gompertz parametric curves fitted to patient level data from 2 to 5 years, 
and American Joint Committee on Cancer registry data from 5 years to 40 years. The 
curves were a good fit to the trial data and consistent with published longer-term data 
for ipilimumab (up to 10 years). Vemurafenib data were taken from the Roche submis-
sion to NICE, with covariate adjustment to account for differences in patient charac-
teristics between trials: M-stage, brain metastases, LDH, gender and ECOG. RESULTS: 
Once a previously untreated patient has survived 2 years, the modelled probability 
of being alive at 5 years is 70.9% for ipilimumab, 44.3% for dacarbazine and 50.2% for 
vemurafenib. At 10 years conditional survival is 45.4%, 28.4% and 31.6%, respectively; 
at 20 years 19.2%, 12.0% and 12.9%. Difference in mean survival was 1.2 years vs dac-
arbazine; 0.4 vs vemurafenib. CONCLUSIONS: A substantial proportion of patients 
treated with ipilimumab surviving to 2 years are likely to have a sustained survival 
benefit: 45.4% of such ipilimumab patients are alive at 10 years and 19.2% at 20 years. 
The level of sustained survival is lower with dacarbazine and vemurafenib.
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OBJECTIVES: NCCN guidelines recommend a serotonin-3 receptor antagonist 
(5-HT3-RA), a substance P/neurokinin 1 (NK1) receptor antagonist, and dexametha-
sone for patients undergoing highly emetogenic chemotherapy (HEC) for the preven-
tion of chemotherapy-induced nausea and vomiting (CINV). This same combination 
is also recommended in patients using moderately emetogenic chemotherapy (MEC) 
at higher risk for CINV. This study estimated the budget impact of adopting netupi-
tant/palonosetron (NEPA), an oral fixed-dose combination of a 5-HT3-RA and an NK1 
for antiemetic prophylaxis, from a U.S. health plan perspective. METHODS: A deci-
sion analytic model compared treatment costs before and after adoption of NEPA 
